{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%231&page=64",
    "query": {
      "intervention": "Formulation #1",
      "page": 64
    },
    "page_size": 10
  },
  "pagination": {
    "page": 64,
    "page_size": 10,
    "total_count": 1760,
    "total_pages": 176,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%231&page=65&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%231&page=63&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-08T23:39:59.774Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00842751",
      "title": "Oral T7 Oral Testosterone in Man",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Healthy Males",
        "Male Contraceptive"
      ],
      "interventions": [
        {
          "name": "First Intervention (7 days)",
          "type": "DRUG"
        },
        {
          "name": "First Washout (7 days)",
          "type": "OTHER"
        },
        {
          "name": "Second Intervention (7 days)",
          "type": "DRUG"
        },
        {
          "name": "Third Intervention (7 days)",
          "type": "DRUG"
        },
        {
          "name": "Second wash-out period",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "MALE",
        "summary": "18 Years to 50 Years · Male only"
      },
      "enrollment_count": 11,
      "start_date": "2009-07",
      "completion_date": "2009-12",
      "has_results": true,
      "last_update_posted_date": "2014-01-13",
      "last_synced_at": "2026-11-08T23:39:59.774Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00842751"
    },
    {
      "nct_id": "NCT02117583",
      "title": "Effects of Food on Oxycodone Pharmacokinetics in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Oxycodone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pain Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 34,
      "start_date": "2014-04",
      "completion_date": "2014-08",
      "has_results": false,
      "last_update_posted_date": "2016-04-04",
      "last_synced_at": "2026-11-08T23:39:59.774Z",
      "location_count": 2,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02117583"
    },
    {
      "nct_id": "NCT06636786",
      "title": "Prevention/Reduction of ASRs and PTSD to Sustain Civilian Performance With Sublingual Cyclobenzaprine HCl (TNX-102 SL)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Stress Reaction",
        "Acute Stress Disorder",
        "Neurocognitive Function",
        "Post-traumatic Stress"
      ],
      "interventions": [
        {
          "name": "Cyclobenzaprine HCl",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 180,
      "start_date": "2025-03-25",
      "completion_date": "2026-11",
      "has_results": false,
      "last_update_posted_date": "2026-10-22",
      "last_synced_at": "2026-11-08T23:39:59.774Z",
      "location_count": 9,
      "location_summary": "Birmingham, Alabama • Indianapolis, Indiana • Kansas City, Kansas + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Camden",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06636786"
    },
    {
      "nct_id": "NCT05850494",
      "title": "Study to Assess Bronchospasm Potentially Induced by Next-Generation Propellant vs HFA Propellant in an MDI in Participants With Well/Partially Controlled Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "HFA MDI",
          "type": "DRUG"
        },
        {
          "name": "HFO MDI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 52,
      "start_date": "2023-05-02",
      "completion_date": "2023-08-21",
      "has_results": true,
      "last_update_posted_date": "2026-02-06",
      "last_synced_at": "2026-11-08T23:39:59.774Z",
      "location_count": 4,
      "location_summary": "North Dartmouth, Massachusetts • St Louis, Missouri • Raleigh, North Carolina + 1 more",
      "locations": [
        {
          "city": "North Dartmouth",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Raleigh",
          "state": "North Carolina"
        },
        {
          "city": "El Paso",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05850494"
    },
    {
      "nct_id": "NCT05501665",
      "title": "Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Lung Non-Small Cell Carcinoma",
        "Stage IV Lung Cancer AJCC v8",
        "Stage III Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Fludeoxyglucose F-18",
          "type": "OTHER"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "[18-F] (fluoropropyl)-L-glutamate (FSPG) PET scan",
          "type": "OTHER"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cemiplimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Atezolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER",
        "BIOLOGICAL",
        "RADIATION"
      ],
      "sponsor": "Vanderbilt-Ingram Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2023-05-09",
      "completion_date": "2027-02-01",
      "has_results": false,
      "last_update_posted_date": "2024-10-17",
      "last_synced_at": "2026-11-08T23:39:59.774Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05501665"
    },
    {
      "nct_id": "NCT04874506",
      "title": "MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM)",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma",
        "Glioblastoma Multiforme"
      ],
      "interventions": [
        {
          "name": "MBM-02",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Matrix Biomed, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "35 Years to 75 Years"
      },
      "enrollment_count": 55,
      "start_date": "2021-06-01",
      "completion_date": "2023-08",
      "has_results": false,
      "last_update_posted_date": "2021-05-05",
      "last_synced_at": "2026-11-08T23:39:59.774Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04874506"
    },
    {
      "nct_id": "NCT01397604",
      "title": "The Effects of GLA on Human Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "GLA-AF",
          "type": "DRUG"
        },
        {
          "name": "GLA-SE",
          "type": "DRUG"
        },
        {
          "name": "Squalene",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Rockefeller University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 32,
      "start_date": "2011-07",
      "completion_date": "2013-03",
      "has_results": false,
      "last_update_posted_date": "2013-09-23",
      "last_synced_at": "2026-11-08T23:39:59.774Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01397604"
    },
    {
      "nct_id": "NCT02397811",
      "title": "Astaxanthin Formulation Bioavailability",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Bioavailability of Astaxanthin Formulations"
      ],
      "interventions": [
        {
          "name": "Enteric Coated Softgels",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Liposomal astaxanthin",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Standard Softgel",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Astaxanthin Water Soluble Emulsion",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Astaxanthin Water Dispersible Powder",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Standard Softgel with Astaxanthin Gel",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Cyanotech Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 12,
      "start_date": "2015-06",
      "completion_date": "2015-12",
      "has_results": false,
      "last_update_posted_date": "2016-08-09",
      "last_synced_at": "2026-11-08T23:39:59.774Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02397811"
    },
    {
      "nct_id": "NCT00791700",
      "title": "An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "Maraviroc",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "2 Years to 18 Years"
      },
      "enrollment_count": 103,
      "start_date": "2009-04-22",
      "completion_date": "2023-06-30",
      "has_results": true,
      "last_update_posted_date": "2020-04-28",
      "last_synced_at": "2026-11-08T23:39:59.774Z",
      "location_count": 18,
      "location_summary": "Los Angeles, California • Orange, California • Wilmington, Delaware + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Wilmington",
          "state": "Delaware"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00791700"
    },
    {
      "nct_id": "NCT04115163",
      "title": "Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Pancreatic Adenocarcinoma",
        "Stage IV Pancreatic Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Anne Noonan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 67,
      "start_date": "2020-06-24",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-12",
      "last_synced_at": "2026-11-08T23:39:59.774Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04115163"
    }
  ]
}